Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | ornithine aminotransferase | 0.0255 | 0.1244 | 1 |
Mycobacterium tuberculosis | Adenosylmethionine-8-amino-7-oxononanoate aminotransferase BioA | 0.1793 | 1 | 1 |
Echinococcus multilocularis | ornithine aminotransferase | 0.0255 | 0.1244 | 1 |
Echinococcus granulosus | ornithine aminotransferase | 0.0255 | 0.1244 | 1 |
Mycobacterium ulcerans | 4-aminobutyrate aminotransferase | 0.0255 | 0.1244 | 0.1244 |
Echinococcus granulosus | Aminotransferase class III | 0.0255 | 0.1244 | 1 |
Mycobacterium ulcerans | L-lysine aminotransferase | 0.0255 | 0.1244 | 0.1244 |
Trypanosoma brucei | metallo-peptidase, Clan MA(E) Family M1 | 0.0036 | 0 | 0.5 |
Echinococcus multilocularis | Aminotransferase class III | 0.0255 | 0.1244 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.1793 | 1 | 1 |
Trypanosoma cruzi | Aminopeptidase M1, putative | 0.0036 | 0 | 0.5 |
Onchocerca volvulus | 0.1503 | 0.8347 | 1 | |
Wolbachia endosymbiont of Brugia malayi | acetylornithine transaminase protein | 0.0255 | 0.1244 | 0.5 |
Schistosoma mansoni | ornithine--oxo-acid transaminase | 0.0255 | 0.1244 | 1 |
Mycobacterium tuberculosis | Probable aminotransferase | 0.1793 | 1 | 1 |
Trichomonas vaginalis | acetylornithine aminotransferase, putative | 0.1793 | 1 | 1 |
Brugia malayi | 4-aminobutyrate aminotransferase, mitochondrial precursor | 0.0255 | 0.1244 | 0.1491 |
Plasmodium falciparum | ornithine aminotransferase | 0.0255 | 0.1244 | 0.5 |
Entamoeba histolytica | aminopeptidase, putative | 0.0036 | 0 | 0.5 |
Brugia malayi | Pax transcription factor protein 2 | 0.1503 | 0.8347 | 1 |
Mycobacterium ulcerans | glutamate-1-semialdehyde aminotransferase | 0.0255 | 0.1244 | 0.1244 |
Trypanosoma cruzi | metallo-peptidase, clan MA(E), family M1, putative | 0.0036 | 0 | 0.5 |
Leishmania major | aminopeptidase-like protein,metallo-peptidase, Clan MA(E), Family M1 | 0.0036 | 0 | 0.5 |
Loa Loa (eye worm) | pax transcription factor protein 2 | 0.1503 | 0.8347 | 1 |
Mycobacterium ulcerans | ornithine aminotransferase RocD1 and RocD2 | 0.0255 | 0.1244 | 0.1244 |
Trypanosoma cruzi | aminopeptidase, putative | 0.0036 | 0 | 0.5 |
Mycobacterium ulcerans | adenosylmethionine-8-amino-7-oxononanoate aminotransferase | 0.1793 | 1 | 1 |
Mycobacterium ulcerans | 4-aminobutyrate aminotransferase | 0.0255 | 0.1244 | 0.1244 |
Trypanosoma brucei | Aminopeptidase M1, putative | 0.0036 | 0 | 0.5 |
Chlamydia trachomatis | glutamate-1-semialdehyde-2,1-aminomutase | 0.0255 | 0.1244 | 0.5 |
Trypanosoma brucei | Aminopeptidase M1, putative | 0.0036 | 0 | 0.5 |
Leishmania major | aminopeptidase, putative,metallo-peptidase, Clan MA(E), Family M1 | 0.0036 | 0 | 0.5 |
Mycobacterium ulcerans | acetylornithine aminotransferase | 0.0255 | 0.1244 | 0.1244 |
Plasmodium vivax | ornithine aminotransferase, putative | 0.0255 | 0.1244 | 0.5 |
Toxoplasma gondii | ornithine aminotransferase, mitochondrial precursor, putative | 0.0255 | 0.1244 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 7 uM | Antileishmanial activity against promastigote form of Leishmania major MHOM/IL/81/BNI after 96 hrs by resazurin-based spectrofluorimetric method | ChEMBL. | 23164660 |
IC50 (ADMET) | = 38 uM | Cytotoxicity against human HeLa cells after 96 hrs by resazurin-based spectrofluorimetric method | ChEMBL. | 23164660 |
Inhibition (functional) | = 95 % | Antileishmanial activity against amastigote form of Leishmania major MHOM/IL/81/BNI infected in Balb/c mouse peritoneal macrophages assessed as inhibition of intracellular amastigote burden at 10 uM after 48 hrs by May-Grunwald-Geimsa staining | ChEMBL. | 23164660 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Leishmania major | ChEMBL23 | 23164660 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.